Headline: Biopharma Investment Climate: Between Uncertainty and Prudence In the face of the mounting uncertainties, venture investors in the biopharma sector are recalibrating their strategies. Private funding, although not as dramatically impacted as public funding, is undergoing a subtle yet significant change. The prevailing winds are now propelling investors towards a more conservative approach, encouraging […]